Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

NCT04315792 is registered in ClinicalTrials.gov with Jina Pharmaceuticals Inc. as lead sponsor.

NCT NCT04315792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04315792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Lead sponsor
Jina Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 3, 2020
Completion date
August 25, 2021
Enrollment
124 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder